Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

403 ARTÍCULOS , VIENDO DEL 256 AL 270

Frontal Lobe Function and Risk of Hip Fracture in Patient With Alzheimer Disease: An Analysis of Linked Data

Roh HW, Hong CH, Lee S, Lee Y, Lee KS, Chang KJ, Oh BH, Choi SH, Kim SY, Back JH, Chung YK, Lim KY, Noh JS, Son SJ.

Medicine (Baltimore). 2015 Nov;94(45):e1918. doi: 10.1097/MD.0000000000001918.

Sudden-On-Chronic Death and Complicated Grief in Bereaved Dementia Caregivers: Two Case Studies of Complicated Grief Group Therapy

Supiano KP, Andersen TC, Haynes LB.

J Soc Work End Life Palliat Care. 2015;11(3-4):267-82. doi: 10.1080/15524256.2015.1107810.

Malnutrition is associated with dementia severity and geriatric syndromes in patients with Alzheimer disease

Yildiz D, Büyükkoyuncu Pekel N, Kiliç AK, Tolgay EN, Tufan F.

Turk J Med Sci. 2015;45(5):1078-81. doi: 10.3906/sag-1406-76.

The connection between MCI and Alzheimer disease: neurocognitive clues

Batum K, Çinar N, Sahin S, Çakmak MA, Karşidağ S.

Turk J Med Sci. 2015;45(5):1137-40. doi: 10.3906/sag-1404-179.

Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays

Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J.

J Alzheimers Dis. 2015;43(1):183-91. doi: 10.3233/JAD-140771.

Cerebrospinal fluid apolipoprotein E concentration and progression of Alzheimer's disease

Schmidt C, Gerlach N, Peter C, Gherib K, Lange K, Friede T, Zerr I.

J Alzheimers Dis. 2015;43(4):1229-36. doi: 10.3233/JAD-141581.

Peripheral biomarkers of Alzheimer's disease

Khan TK, Alkon DL.

J Alzheimers Dis. 2015;44(3):729-44. doi: 10.3233/JAD-142262.

Can multi-modal neuroimaging evidence from hippocampus provide biomarkers for the progression of amnestic mild cognitive impairment?

Chen J, Zhang Z, Li S.

Neurosci Bull. 2015 Feb;31(1):128-40. doi: 10.1007/s12264-014-1490-8. Epub 2015 Jan 16.

Dementia in 2014. Towards early diagnosis in Alzheimer disease

Nordberg A.

Nat Rev Neurol. 2015 Feb;11(2):69-70. doi: 10.1038/nrneurol.2014.257. Epub 2015 Jan 27.

Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities

Reitz C.

Expert Rev Mol Diagn. 2015 Mar;15(3):339-48. doi: 10.1586/14737159.2015.1002469. Epub 2015 Jan 29.

Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies

Lista S, Dubois B, Hampel H.

J Nutr Health Aging. 2015 Feb;19(2):154-63. doi: 10.1007/s12603-014-0515-3.

Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria

Höglund K, Fourier A, Perret-Liaudet A, Zetterberg H, Blennow K, Portelius E.

Clin Chim Acta. 2015 Sep 20;449:3-8. doi: 10.1016/j.cca.2015.01.041. Epub 2015 Feb 7.

Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF

Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, Nairn AC, Croteau P, Schirm M, Allard R, Lamontagne J, Chelsky D, Hoffmann S, Potter WZ; Alzheimer's Disease Neuroimaging Initiative; Foundation for NIH (FNIH) Biomarkers Consortium CSF Proteomics Project Team.

Proteomics Clin Appl. 2015 Aug;9(7-8):715-31. doi: 10.1002/prca.201400178. Epub 2015 Apr 24.

The biomarker and therapeutic potential of miRNA in Alzheimer's disease

Bekris LM, Leverenz JB.

Neurodegener Dis Manag. 2015;5(1):61-74. doi: 10.2217/nmt.14.52.

Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications

Bros P, Delatour V, Vialaret J, Lalere B, Barthelemy N, Gabelle A, Lehmann S, Hirtz C.

Clin Chem Lab Med. 2015 Sep 1;53(10):1483-93. doi: 10.1515/cclm-2014-1048.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias